Company intelligence / Profile preview

Invictus Oncology

New Delhi, Delhi, India

Ownership: Private
Employees: ~14
Development stage: Other

Overview

Invictus Oncology develops novel anticancer therapeutics with a primary focus on triple negative breast cancer. Its pipeline includes next-generation platinum-based chemotherapies designed to improve efficacy and reduce side effects, as well as antibody-drug conjugates using proprietary linker technology aimed at minimizing damage to healthy tissue. The company collaborates with academic institutions, industry partners, and hospitals in India. No published pivotal clinical results are available; the company remains in early clinical development.

Therapeutic areas: Oncology
Modalities: Small molecules (platinum-based chemotherapies)Antibody-drug conjugates (ADCs)
Industry: Biotech

Partnerships

India Innovation Research Centercollaborations with academics/universities/hospitals in India.

Beyond the preview

Go deeper on Invictus Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invictus Oncology.